These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
225 related articles for article (PubMed ID: 31358900)
21. ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells. Zong Y; Xin L; Goldstein AS; Lawson DA; Teitell MA; Witte ON Proc Natl Acad Sci U S A; 2009 Jul; 106(30):12465-70. PubMed ID: 19592505 [TBL] [Abstract][Full Text] [Related]
22. Loss of Nkx3.1 leads to the activation of discrete downstream target genes during prostate tumorigenesis. Song H; Zhang B; Watson MA; Humphrey PA; Lim H; Milbrandt J Oncogene; 2009 Sep; 28(37):3307-19. PubMed ID: 19597465 [TBL] [Abstract][Full Text] [Related]
23. Mutation of the androgen receptor causes oncogenic transformation of the prostate. Han G; Buchanan G; Ittmann M; Harris JM; Yu X; Demayo FJ; Tilley W; Greenberg NM Proc Natl Acad Sci U S A; 2005 Jan; 102(4):1151-6. PubMed ID: 15657128 [TBL] [Abstract][Full Text] [Related]
24. Hedgehog overexpression leads to the formation of prostate cancer stem cells with metastatic property irrespective of androgen receptor expression in the mouse model. Chang HH; Chen BY; Wu CY; Tsao ZJ; Chen YY; Chang CP; Yang CR; Lin DP J Biomed Sci; 2011 Jan; 18(1):6. PubMed ID: 21241512 [TBL] [Abstract][Full Text] [Related]
25. Crosstalk between epithelial-mesenchymal transition and castration resistance mediated by Twist1/AR signaling in prostate cancer. Shiota M; Itsumi M; Takeuchi A; Imada K; Yokomizo A; Kuruma H; Inokuchi J; Tatsugami K; Uchiumi T; Oda Y; Naito S Endocr Relat Cancer; 2015 Dec; 22(6):889-900. PubMed ID: 26311513 [TBL] [Abstract][Full Text] [Related]
26. Klf5 deletion promotes Pten deletion-initiated luminal-type mouse prostate tumors through multiple oncogenic signaling pathways. Xing C; Ci X; Sun X; Fu X; Zhang Z; Dong EN; Hao ZZ; Dong JT Neoplasia; 2014 Nov; 16(11):883-99. PubMed ID: 25425963 [TBL] [Abstract][Full Text] [Related]
27. Development, progression, and androgen-dependence of prostate tumors in probasin-large T antigen transgenic mice: a model for prostate cancer. Kasper S; Sheppard PC; Yan Y; Pettigrew N; Borowsky AD; Prins GS; Dodd JG; Duckworth ML; Matusik RJ Lab Invest; 1998 Jun; 78(6):i-xv. PubMed ID: 9645768 [TBL] [Abstract][Full Text] [Related]
28. The Master Neural Transcription Factor BRN2 Is an Androgen Receptor-Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer. Bishop JL; Thaper D; Vahid S; Davies A; Ketola K; Kuruma H; Jama R; Nip KM; Angeles A; Johnson F; Wyatt AW; Fazli L; Gleave ME; Lin D; Rubin MA; Collins CC; Wang Y; Beltran H; Zoubeidi A Cancer Discov; 2017 Jan; 7(1):54-71. PubMed ID: 27784708 [TBL] [Abstract][Full Text] [Related]
29. Development, progression, and androgen-dependence of prostate tumors in probasin-large T antigen transgenic mice: a model for prostate cancer. Kasper S; Sheppard PC; Yan Y; Pettigrew N; Borowsky AD; Prins GS; Dodd JG; Duckworth ML; Matusik RJ Lab Invest; 1998 Mar; 78(3):319-33. PubMed ID: 9520945 [TBL] [Abstract][Full Text] [Related]
30. The comprehensive role of E-cadherin in maintaining prostatic epithelial integrity during oncogenic transformation and tumor progression. Olson A; Le V; Aldahl J; Yu EJ; Hooker E; He Y; Lee DH; Kim WK; Cardiff RD; Geradts J; Sun Z PLoS Genet; 2019 Oct; 15(10):e1008451. PubMed ID: 31658259 [TBL] [Abstract][Full Text] [Related]
31. The NLR-related protein NWD1 is associated with prostate cancer and modulates androgen receptor signaling. Correa RG; Krajewska M; Ware CF; Gerlic M; Reed JC Oncotarget; 2014 Mar; 5(6):1666-82. PubMed ID: 24681825 [TBL] [Abstract][Full Text] [Related]
32. CHD1 Loss Alters AR Binding at Lineage-Specific Enhancers and Modulates Distinct Transcriptional Programs to Drive Prostate Tumorigenesis. Augello MA; Liu D; Deonarine LD; Robinson BD; Huang D; Stelloo S; Blattner M; Doane AS; Wong EWP; Chen Y; Rubin MA; Beltran H; Elemento O; Bergman AM; Zwart W; Sboner A; Dephoure N; Barbieri CE Cancer Cell; 2019 Apr; 35(4):603-617.e8. PubMed ID: 30930119 [TBL] [Abstract][Full Text] [Related]
33. Aberrant activation of hepatocyte growth factor/MET signaling promotes β-catenin-mediated prostatic tumorigenesis. Aldahl J; Mi J; Pineda A; Kim WK; Olson A; Hooker E; He Y; Yu EJ; Le V; Lee DH; Geradts J; Sun Z J Biol Chem; 2020 Jan; 295(2):631-644. PubMed ID: 31819003 [TBL] [Abstract][Full Text] [Related]
34. CtBP2 modulates the androgen receptor to promote prostate cancer progression. Takayama K; Suzuki T; Fujimura T; Urano T; Takahashi S; Homma Y; Inoue S Cancer Res; 2014 Nov; 74(22):6542-53. PubMed ID: 25228652 [TBL] [Abstract][Full Text] [Related]
35. HOXC8 inhibits androgen receptor signaling in human prostate cancer cells by inhibiting SRC-3 recruitment to direct androgen target genes. Axlund SD; Lambert JR; Nordeen SK Mol Cancer Res; 2010 Dec; 8(12):1643-55. PubMed ID: 21047772 [TBL] [Abstract][Full Text] [Related]
36. Loss of MyD88 leads to more aggressive TRAMP prostate cancer and influences tumor infiltrating lymphocytes. Peek EM; Song W; Zhang H; Huang J; Chin AI Prostate; 2015 Apr; 75(5):463-73. PubMed ID: 25597486 [TBL] [Abstract][Full Text] [Related]
37. Inactivation of androgen-induced regulator ARD1 inhibits androgen receptor acetylation and prostate tumorigenesis. Wang Z; Wang Z; Guo J; Li Y; Bavarva JH; Qian C; Brahimi-Horn MC; Tan D; Liu W Proc Natl Acad Sci U S A; 2012 Feb; 109(8):3053-8. PubMed ID: 22315407 [TBL] [Abstract][Full Text] [Related]